Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2024-01-11 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a disclosure about changes in shareholder equity due to a non-transactional transfer of shares between two shareholders following a divorce agreement. It details the shareholding percentages before and after the change, confirms no change in control or actual controller, and includes commitments regarding shareholding and restrictions on share sales. It references a "简式权益变动报告书" (Simplified Equity Change Report) filed on the same day. The document is a formal announcement of a change in major shareholding but does not contain financial statements or detailed financial analysis. It is not a full report but a regulatory announcement about shareholding changes. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short (2110 characters), consistent with a notification rather than a full report.
2024-01-11 Chinese
简式权益变动报告书（金磊、王思勉）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding between two individuals, including the number of shares before and after the change, the reason for the change (divorce property division), and the method of transfer (non-trade transfer through the securities registration company). It includes detailed information about the shareholders, their holdings, and legal declarations. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of changes in significant share ownership levels, consistent with the definition of a Major Shareholding Notification (MRQ). The document length is sufficient and contains substantive content about shareholding changes, not just an announcement or certification. Therefore, the appropriate classification is MRQ.
2024-01-11 Chinese
关于控股子公司重组人促卵泡激素注射液获得《药品注册证书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval and issuance of a drug registration certificate by the National Medical Products Administration for a product of a controlling subsidiary. It is a regulatory announcement about a product approval, not a financial report, management change, or shareholder meeting material. The document is short (603 characters) and serves as a formal public disclosure of regulatory approval. It does not contain financial data, management discussion, or voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-09 Chinese
关于控股子公司EG017软膏获得药物临床试验批准的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (696 characters) from Changchun High-tech Industry Group Co., Ltd. regarding the approval of a clinical trial for a drug (EG017 ointment) by the National Medical Products Administration. It contains no financial data, no mention of financial results, no detailed report or presentation, and no regulatory certification. It is an announcement about a regulatory approval related to clinical trials, not a financial report or management change. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a legal proceeding or merger announcement. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-01-08 Chinese
关于控股子公司亮丙瑞林注射乳剂临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Changchun High-tech Industry Group Co., Ltd. regarding the approval of a clinical trial application for a drug by its subsidiary. It includes a regulatory approval notice from the National Medical Products Administration and a caution about investment risks. The document is brief (493 characters) and does not contain financial data, earnings, or management discussion. It is an official announcement about a regulatory approval related to clinical trials, not a financial report or management change. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-12-28 Chinese
关于控股子公司注射用GenSci125临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (700 characters) from Changchun High-tech Industry Group Co., Ltd. regarding the approval of a clinical trial application for a drug by its subsidiary. It is an official notice about regulatory approval from the National Medical Products Administration. There is no financial data, no detailed report, no management discussion, or earnings information. The document is an announcement of a regulatory event related to clinical trial approval, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like financial reports, management changes, or capital updates.
2023-12-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.